14-day Premium Trial Subscription Try For FreeTry Free
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings e
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet

VYNE Gains on Preclinical Data for IPF Candidate

12:57pm, Thursday, 20'th Apr 2023
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differ
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differe
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differe

3 Penny Stocks Under $1 That Are on Fire Today

02:24pm, Thursday, 07'th Apr 2022
Are these under $1 penny stocks worth buying this month? The post 3 Penny Stocks Under $1 That Are on Fire Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE